Your browser doesn't support javascript.
loading
BET Inhibition Enhances TNF-Mediated Antitumor Immunity.
Wellinger, Lisa C; Hogg, Simon J; Newman, Dane M; Friess, Thomas; Geiss, Daniela; Michie, Jessica; Ramsbottom, Kelly M; Bacac, Marina; Fauti, Tanja; Marbach, Daniel; Jarassier, Laura; Thienger, Phillip; Paehler, Axel; Cluse, Leonie A; Kearney, Conor J; Vervoort, Stephin J; Trapani, Joseph A; Oliaro, Jane; Shortt, Jake; Ruefli-Brasse, Astrid; Rohle, Daniel; Johnstone, Ricky W.
Afiliação
  • Wellinger LC; Roche Pharma Research and Early Development, Oncology Discovery, Roche Innovation Center Basel, Basel, Switzerland.
  • Hogg SJ; Translational Hematology Program, Peter MacCallum Cancer Centre, Melbourne, Australia.
  • Newman DM; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Australia.
  • Friess T; Translational Hematology Program, Peter MacCallum Cancer Centre, Melbourne, Australia.
  • Geiss D; Roche Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.
  • Michie J; Roche Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.
  • Ramsbottom KM; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Australia.
  • Bacac M; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia.
  • Fauti T; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia.
  • Marbach D; Roche Pharma Research and Early Development, Oncology Discovery, Roche Innovation Center Zurich, Schlieren, Switzerland.
  • Jarassier L; Roche Pharma Research and Early Development, Oncology Discovery, Roche Innovation Center Zurich, Schlieren, Switzerland.
  • Thienger P; Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, Basel, Switzerland.
  • Paehler A; Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, Basel, Switzerland.
  • Cluse LA; Department for BioMedical Research, University of Bern, Bern, Switzerland.
  • Kearney CJ; Roche Pharma Research and Early Development, Oncology Discovery, Roche Innovation Center Basel, Basel, Switzerland.
  • Vervoort SJ; Translational Hematology Program, Peter MacCallum Cancer Centre, Melbourne, Australia.
  • Trapani JA; Translational Hematology Program, Peter MacCallum Cancer Centre, Melbourne, Australia.
  • Oliaro J; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Australia.
  • Shortt J; Translational Hematology Program, Peter MacCallum Cancer Centre, Melbourne, Australia.
  • Ruefli-Brasse A; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Australia.
  • Rohle D; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Australia.
  • Johnstone RW; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia.
Cancer Immunol Res ; 10(1): 87-107, 2022 01.
Article em En | MEDLINE | ID: mdl-34782346
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteínas Nucleares / Neoplasias Colorretais / Ubiquitina-Proteína Ligases / Proteínas Inibidoras de Apoptose / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: Cancer Immunol Res Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Suíça
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteínas Nucleares / Neoplasias Colorretais / Ubiquitina-Proteína Ligases / Proteínas Inibidoras de Apoptose / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: Cancer Immunol Res Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Suíça